Clinical trial and safety of oxaliplatin combined with tegafur in the treatment of advanced colorectal cancer patients
10.13699/j.cnki.1001-6821.2017.16.007
- VernacularTitle:奥沙利铂联合替吉奥治疗晚期结肠癌患者的临床疗效与安全性
- Author:
Cui-Ling SUN
1
;
Xiao-Yu XU
;
Ying-Ying GAO
;
Tian TIAN
;
Feng LI
Author Information
1. 阜阳市人民医院肿瘤内科
- Keywords:
oxaliplatin;
tegafur;
advanced colorectal cancer;
cancer embryonic antigen
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(16):1540-1542
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of oxaliplatin combined with tegafur in the treatment of advanced colorectal cancer(ACC).Methods Forty-eight cases of patients with ACC were randomly divided into the control group and treatment group,24 cases in each group.The control group was given intravenous infusion of oxaliplatin 130 mg· m-2 + oral capecitabine1 g · m-2,bid;the treatment group was given intravenous infusion of oxaliplatin130 mg · m-2 + tegafur 40 mg · m-2,bid;two groups of patients with a cycle of 21 days,a total of 4 cycles of treatment.Before and after treatment,The levels of serum cancer embryonic antigen (CEA),alpha fetal protein (AFP),carbohydrate antigen 19-9 (CA19-9),cytoplasmic thymidine kinase 1 (TK1) were determined in order to compare between the two groups.Results After treatment,the serum levels of CEA,AFP in control group and treatment group were (21.45 ± 3.06),(15.34 ± 2.18);(9.74 ± 1.32),(5.11 ±0.73)ng · mL-1;the serum levels of CA19-9 in the two groups were (162.43 ± 21.45),(135.68 ± 17.45) U · mL-1;the serum levels of TK1 in the two groups were (1.98 ± 0.26),(1.11 ± 0.14)pmol · L-1.Compared with the control group,the serum levels of CEA,AFP,CA19-9 and TK1 were lowerer than treatment group with significantly(all P ＜0.05).The efficiency of the treatment group (83.33％) was significantly higher than that of the control group (66.66％,P ＜ 0.05).The incidence of adverse drugs reactions of the treatment group (58.33％) was significantly lower than that of the control group (79.17％,P ＜0.05),the results were statistically significant.Conclusion The oxaliplatin combined with tegafur can significantly reduce the serum levels of CEA,AFP,CA19-9 and TK1 in patients with advanced colorectal cancer,improve clinical efficacy and safety.
